Pregnancy Category: C
Diagnosis of myasthenia gravis.Assessment of adequacy of anticholinesterase therapy in myasthenia gravis.Differentiating myasthenic from cholinergic crisis.Reversal of muscle paralysis from nondepolarizing neuromuscular blocking agents.
Inhibits the breakdown of acetylcholine so that it accumulates and has a prolonged effect. Effects include miosis; increased intestinal and skeletal muscle tone; bronchial constriction; bradycardia; increased salivation, lacrimation, and sweating.
Short-lived improvement in muscular function in patients with myasthenia gravis.
Reversal of nondepolarizing neuromuscular blocking agents.
Absorption: Absorption following IM and subcut administration not known.
Distribution: 1.1 L/kg.
Metabolism and Excretion: Unknown.
Half-life: 73–126 min.
Time/action profile (cholinergic activity)
|IM||2–10 min||unknown||5–30 min|
|IV||30–60 sec||unknown||10 min|
Contraindicated in: Hypersensitivity; Mechanical obstruction of the GI or GU tract; Hypersensitivity to bisulfites; Obstetric: May cause uterine irritability after IV administration near term; newborns may display muscle weakness; Lactation: Lactation.
Use Cautiously in: History of asthma; Cardiovascular disease; Because some patients may be extremely sensitive to the effects of anticholinesterases, atropine should be available in case of excessive dosage.
Adverse Reactions/Side Effects
Central nervous system
- seizures (life-threatening)
Ear, Eye, Nose, Throat
- bronchospasm (most frequent)
- excess secretions (most frequent)
- bradycardia (most frequent)
- abdominal cramps (most frequent)
- diarrhea (most frequent)
- excess salivation (most frequent)
- vomiting (most frequent)
- urinary frequency
- sweating (most frequent)
Drug-Drug interactionAction may be antagonized by drugs possessing anticholinergic properties, including antihistamines, antidepressants, atropine, haloperidol, phenothiazines, quinidine, and disopyramide.Prolongs action of depolarizing muscle-relaxing agents (succinylcholine, decamethonium ).May lead to ↑ bradycardia in patients receiving digoxin.Angel's trumpet, jimson weed, and scopolia may antagonize cholinergic effects.
Route/DosageDiagnosis of Myasthenia Gravis
Intravenous (Adults) 2 mg; if no response, administer an additional 8 mg after 45 sec; may repeat test in 30 min. If cholinergic response occurs after initial 2 mg dose, administer atropine 0.4–0.5 mg IV. Patients >50 yr should be pretreated with atropine to prevent bradycardia/hypotension.
Intravenous (Children >34 kg) 2 mg; if no response after 45 sec, may administer 1 mg every 30–45 sec to a total of 10 mg.
Intravenous (Children <34 kg) 1 mg; if no response after 45 sec, may administer 1 mg every 45 sec to a total of 5 mg.
Intravenous (Infants) 0.5 mg.
Intramuscular (Adults) 10 mg. If cholinergic response occurs, may repeat 2-mg dose in 30 min to rule out false-negative reaction. Patients >50 yr should be pretreated with atropine to prevent bradycardia/hypotension.
Intramuscular (Children >34 kg) 5 mg.
Intramuscular (Children <34 kg) 2 mg.Assessment of Anticholinesterase Therapy
Intravenous (Adults) 1–2 mg 1 hr after oral anticholinesterase dose.Differentiation of Cholinergic from Myasthenic Crisis
Intravenous (Adults) 1 mg; may give additional 1 mg 1 min later.Reversal of Nondepolarizing Neuromuscular Blocking Agents
Intravenous (Adults) 10 mg; may repeat as needed (not to exceed 40 mg). Doses of 0.5–1 mg/kg have been used.
Injection: 10 mg/mLIn combination with: atropine (Enlon-Plus). (See combination drugs).
- Assess neuromuscular status (ptosis, diplopia, vital capacity, ability to swallow, extremity strength) prior to and immediately after administration.
- Reversal of nondepolarizing neuromuscular blocking agents is more rapid in pediatric patients.
Atropine may be used for treatment of cholinergic symptoms. Oxygen and resuscitation equipment should be available.
- To differentiate myasthenic from cholinergic crisis, assess for increased weakness, diaphoresis, increased saliva and bronchial secretions, dyspnea, nausea, vomiting, diarrhea, and bradycardia. If these symptoms occur after administration of edrophonium, patient is in cholinergic crisis. If strength improves after administration of edrophonium, patient is in myasthenic crisis.
Potential Nursing DiagnosesIneffective breathing pattern (Indications)
- For myasthenia gravis patients, diagnostic IV dose and dose to differentiate myasthenic from cholinergic crisis should be administered by a physician.
- Diluent: Administer undiluted with a tuberculin syringe. Concentration: 10 mg/mL.
- Rate: Administer doses over 30–45 sec.
- Y-Site Compatibility: heparin, hydrocortisone, potassium chloride, vitamin B complex with C
- Inform patient that the effects of this medication last up to 30 min.
- Relief of myasthenic symptoms.
- Differentiation of myasthenic from cholinergic crisis.
- Reversal of paralysis after anesthesia.
a trademark for an anticholinesterase drug (edrophonium).
Tensilon®Edrophonium chloride Pharmacology A short-acting anticholinesterase used to diagnose myasthenia gravis and reverse the effects of nondepolarizing neuromuscular blockers. See Myasthenia gravis, Reversal agent.
trademark for edrophonium chloride; used in the diagnosis of myasthenia gravis, known as the Tensilon test.